Skip to main content

Gilead Sciences

Gilead Sciences, Inc. is an American biopharmaceutical enterprise that discovers, develops, manufactures, and commercializes innovative human therapeutics for life-threatening diseases. The company structures its drug discovery and commercial operations across key therapeutic focus areas: HIV/AIDS, liver diseases including hepatitis B and C, oncology, and cell therapy. Its commercial drug portfolio includes market-leading therapies such as Biktarvy, Descovy, and Genvoya for HIV management, Veklury for COVID-19, Epclusa for hepatitis, Trodelvy, and CAR-T cell therapy Yescarta. Principal revenue drivers comprise global commercial sales of proprietary, patent-protected prescription biopharmaceuticals, complemented by royalties and strategic research licensing partnerships. Gilead serves broad end markets including wholesale drug distributors, retail pharmacy chains, hospital systems, government health programs, and patients across North America, Europe, and international markets. The enterprise occupies a market-leading position as the world's primary provider of HIV antiretroviral therapies and a pioneer in viral disease treatments. Headquartered in Foster City, California, the company's common stock is listed on the Nasdaq Global Select Market under the ticker symbol GILD and is included in the S&P 500 index.

133 of the funds FundTelligence covers report a position in Gilead Sciences.

Legal name
GILEAD SCIENCES INC
Sector
Health Care
Country
United States
Funds holding it
133

Funds holding Gilead Sciences

Showing the 8 largest of 133 funds holding it.

Loading...